Home > News > Headline News

News

Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

New Phase 2b Clinical Trial for MBC Patients treated with Avastin(R)

February 16, 2008

By MedicalNewsToday.com

Accelerated Community Oncology Research Network, Inc. (ACORN), announced the initiation of a Phase 2b clinical trial evaluating the efficacy of Nexavar(R) (sorafenib) tablets in combination with the anticancer drug gemcitabine (Gemzar(R)) in patients with metastatic breast cancer whose cancer has progressed during or after treatment with bevacizumab (Avastin(R)).

The double-blind, randomized trial will enroll a total of 220 patients at approximately 45 sites in approximately 20 states and will assess efficacy, safety and patient quality of life as endpoints. Patients will be randomly assigned to receive either Nexavar and gemcitabine, or placebo and gemcitabine.

Genentech’s Avastin does well in breast cancer test

February 14, 2008

By SanFrancisco Business Times

Genentech Inc. said Tuesday that its drug Avastin did well in a Phase III trial in combination with another treatment against breast cancer.

Neuroscientists Offer Hope For Breast Cancer Patients Suffering From ‘Chemobrain’

February 9, 2008

By MedicalNewsToday.com

Mental function in cancer patients with “chemobrain” can be improved by training with the Posit Science (R) Brain Fitness Program.  The data will be presented by researchers at the International Neuropsychological Society’s annual meeting.

Nineteen breast cancer patients, all women, who underwent chemotherapy and reported having “chemobrain” participated in the study.

Tumor-Specific Imaging for Breast Cancer at Thomas Jefferson University

February 7, 2008

By PR Newswire

PARK CITY, Utah -- NuView Radiopharmaceuticals, Inc. (NuView) has executed an agreement with Thomas Jefferson University (Jefferson) for the exclusive distribution and commercialization rights for a tumor-specific imaging agent that assists in the diagnosis of breast and prostate tumors. NuView also intends to sponsor research at Jefferson to further develop the technology.

Resistance To Breast Cancer Treatment Determined By Unsuspected Protein

February 6, 2008

By ScienceDaily

An innovative research approach has identified a previously unsuspected protein as a key player in the resistance to particular forms of breast cancer therapy. The study, published by Cell Press in the February issue of Cancer Cell, significantly advances the understanding of the molecular response to breast cancer therapies that target estrogen signaling.

Epoetin Beta Has Little Effect in Metastatic Breast Cancer

February 5, 2008

By ModernMedicine.com

In patients with metastatic breast cancer who receive anthracycline- and/or taxane-based chemotherapy and develop anemia, epoetin beta increases hemoglobin levels but does not improve overall survival, researchers report in the Feb. 1 issue of the Journal of Clinical Oncology.  

Two Studies Identify Drivers of Metastases

January 23, 2008

By NCI Cancer Bulletin

A new study has pinpointed tiny strands of RNA that help suppress breast cancer metasteses.

A study published in the January 10 Nature has pinpointed several microRNAs (miRNAs) - tiny RNA strands that regulate gene expression - that help suppress breast cancer metastases.

Researchers from Memorial Sloan-Kettering Cancer Center examined miRNAs in breast cancer cell lines that were highly metastatic to bone and lung compared with control breast cancer cell lines. They chose to focus further studies on the six miRNAs whose expression was most decreased in the metastatic cells.

Errors in tests for Her-2 and ER status

January 5, 2008

By Wall Street Journal

Bad Cancer Tests Drawing Scrutiny

In a study published in 2006 on Her-2 tests — led by researchers at Genentech — a large laboratory that is experienced in the procedures reviewed tests performed by local labs around the country. It found that 14% to 16% of those judged positive for Her-2 were actually negative. Of those judged negative, 18% to 23% were in fact positive.

After signs of problems with hormone testing at a lab in Newfoundland, tissue from 763 patients with negative results was retested at a different lab in 2005 and 2006. The new tests concluded that 317 of those were actually positive. Officials at the provincial Eastern Regional Health Authority in Newfoundland, which oversees the lab that had inaccurate tests, said they can’t comment on potential causes for the problems because of an ongoing government inquiry and a class-action suit by patients. But they said the authority did pursue the issue.

In another analysis of labs in multiple countries, published online last August in the Journal of Clinical Oncology, 70% of 105 patients scored as negative on the estrogen test were relabeled as positive when the tissue was retested by an experienced lab. The analysis found that positive results were almost always correct.

Bad Cancer Tests Drawing Scrutiny

January 4, 2008

By Anna Wilde Mathews, Wall Street Journal

Thousands of breast-cancer patients may be getting the wrong treatment because of errors in two laboratory tests widely used to determine which drugs are prescribed.

MBCN Blog

January 2, 2008

Welcome to the MBCN blog!

Visit this blog  to track news and discussions regarding metastatic breast cancer.

‹ First  < 49 50 51